• COMPANY

Vision & Mission

Corporate culture

Respect

We will build mutually synergistic and beneficial relationships with the spirit of mutual respect and consideration for society as well as our customers and employees. We will continue to practice transparent management and contribute to the development of the social community to become a trusted and loved corporate citizen.

Quality of Life

We will provide products that satisfy unmet needs and bring convenience to life to stay ahead as a leader in improving the quality and value of our customers’ lives.

Excellency

We are dedicated to horizontal culture, creative thinking, taking on challenges to fulfill dreams, and outstanding performance to create a dynamic organizational culture full of passion and enthusiasm to make sure our capacity remains best-in-class.

Integrity

Only members with self-satisfaction and pride pursue heartfelt development. We ensure that individual integrity results in departmental integrity, corporate integrity, and then social integrity to offer an opportunity and an environment where all members are deeply moved.

History

  •  

    2025

    • Vivle Inj. approved by MFDS (Korea)
    • Selected for a government project led by the Korea Disease Control and Prevention Agency
  •  

    2024

    • Hitox Inj. 100units, Hemofence Hemostatic approved by MFDS (Korea)
  •  

    2023

    • Hitox 50unit, 200unit approved by MFDS (Korea)
  •  

    2022

    • Expanded the Uiwang Central Research Center and office
    • Completed construction of the Osong biopharmaceutical ingredient cGMP plant
    • Reverdion Inj., Qfens hemostatic, HemoShield Hemostatic approved by MFDS (Korea)
  •  

    2021

    • Began construction of the Osong biopharmaceutical ingredient cGMP plant
    • Neoronin, Endostopi Hemostatic approved by MFDS (Korea)
  •  

    2020

    • Designated as an Innovative Pharmaceutical Company by the Ministry of Health and Welfare in Korea
    • Botulinum toxin formulation obtained permission for export
    • Stopi Hemostatic approved by MFDS (Korea)
  •  

    2019

    • Botulinum toxin formulation approved by IND
  •  

    2018

    • Selected as a local star company
    • The new aseptic factory was approved for cGMP
  •  

    2017

    • Built the cGMP aseptic factory
  •  

    2015

    • Selected as a leading company of Jeju
  •  

    2014

    • Government project : Development of a cosmetic ingredient, PDRN from amberjack milt in Jeju (Polydeoxyribonucleotide)
  •  

    2013

    • Establishment of Jeju API facility and BGMP approval by KFDA
    • Government project: Development of combination drug preventing after-cataract
    • Development of a new drug for lymphocytopenia treatment
  •  

    2011

    • Hirax Inj. approved by MFDS (Korea)
    • Government project: Treatment for metastatic renal cell carcinoma(mRCC) (human recombinant interlukin-2)
  •  

    2010

    • Jeju Plant’s approval of cGMP by the Ministry of Food and Drug Safety (injections and solid oral dosage forms)
  •  

    2009

    • Started construction of Jeju cGMP plant
  •  

    2007

    • Started exporting pharmaceutical drugs – Southeast Asia, Middle East, and South America
  •  

    2006

    • Certified as a startup, acquired certification for the corporate research institute
  •  

    2005

    • Established BMI KOREA Co., Ltd.
    • Acquired the GMP factory in Hyangnam Pharmaceutical Complex, Hwaseong

Global Business

BMI KOREA is set to rise as a global healthcare leader that contributes to the wholesome life of humankind.

Europe

Netherlands
Spain
Italy
Russia,
Ukraine

Middle East

Saudi Arabia
Iran
Iraq
Lebanon
Jordan
Kuwait

Africa

Egypt

Asia

China
Vietnam
Singapore
Japan
Taiwan
Thailand
Philippines
Pakistan
Myanmar
Mongolia
Indonesia

Eurasia

Russia
Ukraine
Uzbekistan

North America

United States

South America

Brazil
Bolivia